GSK and J&J alum Vijay Reddy to take control of R&D at Tmunity; Andrew Hirsch exits Agios for CEO job at C4 Therapeutics
→ Vijay Reddy was seeking a return to the US when he left his role as CMO at London-based Autolus this summer. Philadelphia is that landing spot, as the T cell immunotherapy player Tmunity has put him in charge of R&D.
Reddy arrives at the Penn spinout with plenty of Big Pharma bona fides after developing the CAR-T cell clinical program at Autolus. Tmunity’s new chief R&D officer was a senior director and led early clinical development at J&J subsidiary Janssen from 2013-16, and from 2009-13, he was GSK’s medical director, cancer research and clinical development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.